Figure 3.
Figure 3. DC viability in response to treatment with bortezomib. (A) DCs generated from adherent monocytes by culture in the presence of GM-CSF and IL-4 were harvested at day 6 of culture and treated for 24 hours with the indicated concentrations of bortezomib. Thereafter, cells were harvested and stained with 5 μg/mL PI, and PIneg (viable) DCs were enumerated by flow cytometry. Means of triplicates with SDs are presented. *P < .05 (B) Adherent monocyte-derived DCs were cultured in the presence of GM-CSF and IL-4 for 6 days. Thereafter, cells were stimulated for 24 hours with or without TNF-α (20 ng/mL) or LPS (200 ng/mL) in the presence or absence of 5 ng/mL bortezomib. Cells were subsequently harvested, stained with PI, and analyzed by flow cytometry. Results are shown as means of triplicates with SDs.

DC viability in response to treatment with bortezomib. (A) DCs generated from adherent monocytes by culture in the presence of GM-CSF and IL-4 were harvested at day 6 of culture and treated for 24 hours with the indicated concentrations of bortezomib. Thereafter, cells were harvested and stained with 5 μg/mL PI, and PIneg (viable) DCs were enumerated by flow cytometry. Means of triplicates with SDs are presented. *P < .05 (B) Adherent monocyte-derived DCs were cultured in the presence of GM-CSF and IL-4 for 6 days. Thereafter, cells were stimulated for 24 hours with or without TNF-α (20 ng/mL) or LPS (200 ng/mL) in the presence or absence of 5 ng/mL bortezomib. Cells were subsequently harvested, stained with PI, and analyzed by flow cytometry. Results are shown as means of triplicates with SDs.

Close Modal

or Create an Account

Close Modal
Close Modal